News

Maker of Ozempic and Wegovy broke advertising rules, regulator finds
The maker of weight loss drugs Ozempic and Wegovy broke rules around the advertising and marketing of its medication to ...
FDA cracking down on Ozempic copycats, potentially slimming options for consumers
The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and ...
The New York Sun4d
Millions of Americans Face Sticker Shock From Weight Loss Drugs as FDA Bars Production of Cheaper Versions of Ozempic, Others
Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...
Wegovy maker Novo faces fee demand after losing copycat drug lawsuit
(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...
FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...
Endocrinology Advisor1d
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.
STAT9d
Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...
Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests
After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...